Section 1: Introductory Statements and Governance

1ISG-010

REAL-WORLD EVIDENCE OF HIGH-COST DRUGS FOR METASTATIC MELANOMA: EFFECTIVENESS, COMPLIANCE TO CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION

1ISG-009

AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL

1ISG-008

FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT?

1ISG-007

PEMETREXED´S LESSON

1ISG-006

HEPATITIS C TREATMENT: COST AND EFFECTIVENESS

1ISG-005

A COST EFFECTIVE STRATEGY: SWITCHING FROM ONE TO TWO TABLETS, IN A ONCE-DAILY REGIMEN IN HIV PATIENTS

1ISG-004

ABSTRACT WITHDRAWN

1ISG-003

BIOSIMILAR GROWTH HORMONE: DEFINED DAILY DOSE IN AN ITALIAN DISTRICT AFTER THE REGIONAL TENDER

1ISG-002

BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD-LEVEL HOSPITAL

1ISG-001

HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS ONE YEAR AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRALS

1ISG-021

PROCEDURAL KITS WITH MEDICAL DEVICES FOR EYE SURGERY: OPTIMISATION STRATEGY

1ISG-018

EVALUATION OF THE ECONOMIC SUSTAINABILITY OF A ROBOTIC SYSTEM FOR CHEMOTHERAPY COMPOUNDING

1ISG-017

ANALYSIS OF PRESCRIBING QUALITY INDEX (PQI) IN HOSPITAL CARE AND STRATEGIES FOR IMPROVEMENT

1ISG-016

EVALUATION OF SUBSTITUTION AND SWITCH TO ETANERCEPT BIOSIMILAR AND RELATED COST SAVINGS

1ISG-015

MULTIPLE SCLEROSIS COMMITTEE: INCLUDING A PHARMACIST AS PART OF THE MULTIDISCIPLINARY TEAM

Pages